ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,842.91
0.11%
Dow Jones
42,518.28
0.52%
US Dollar vs MXN
20.53555
0.09%
Brent Oil
79.235
-0.58%
Bitcoin
96,976.29
0.49%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Molecular Partners AG (MOLN) Cotización

Molecular Partners AG

Molecular Partners AG (MOLN)

NASDAQ
5.36
-0.04
(-0.65%)
Cerrado 14 Enero 3:00PM
Delayed by 15 minutes
5.36
0.00
( 0.00% )
Pre Mercado: 3:04AM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
5.36
Postura de Compra
5.39
Postura de Venta
5.77
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
194.859M
Precio Anterior
5.36
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
36,354,297
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-14.78
Beneficio por acción (BPA)
-1.71
turnover
7.04M
Beneficio neto
-61.98M

Acerca de Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.molecularpartners.com
Sede
Schlieren, Che
Fundado
-
Molecular Partners AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MOLN. The last closing price for Molecular Partners was US$5.36. Over the last year, Molecular Partners shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Molecular Partners currently has 36,354,297 shares in issue. The market capitalisation of Molecular Partners is US$194.86 million. Molecular Partners has a price to earnings ratio (PE ratio) of -14.78.

MOLN Últimas noticias

Más noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

13 Enero 2025
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

13 Enero 2025
Edgar (US Regulatory)

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the...

12 Enero 2025
GlobeNewswire Inc.

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

17 Diciembre 2024
GlobeNewswire Inc.

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...

08 Diciembre 2024
GlobeNewswire Inc.

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a...

07 Noviembre 2024
GlobeNewswire Inc.

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin...

05 Noviembre 2024
GlobeNewswire Inc.

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data...

31 Octubre 2024
GlobeNewswire Inc.

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

25 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

MOLN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Molecular Partners?
El precio actual de las acciones de Molecular Partners es US$ 5.36
¿Cuántas acciones de Molecular Partners están en circulación?
Molecular Partners tiene 36,354,297 acciones en circulación
¿Cuál es la capitalización de mercado de Molecular Partners?
La capitalización de mercado de Molecular Partners es USD 194.86M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Molecular Partners?
Molecular Partners ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Molecular Partners?
El ratio precio/beneficio de Molecular Partners es -14.78
¿Cuál es el ratio de efectivo a ventas de Molecular Partners?
El ratio de efectivo a ventas de Molecular Partners es 130.17
¿Cuál es la moneda de reporte de Molecular Partners?
Molecular Partners presenta sus resultados financieros en CHF
¿Cuál es el último ingresos anual de Molecular Partners?
El último ingresos anual de Molecular Partners es CHF 7.04M
¿Cuál es el último beneficio anual de Molecular Partners?
El último beneficio anual de Molecular Partners es CHF -61.98M
¿Cuál es la dirección registrada de Molecular Partners?
La dirección registrada de Molecular Partners es WAGISTRASSE 14, SCHLIEREN, 8952
¿Cuál es la dirección del sitio web de Molecular Partners?
La dirección del sitio web de Molecular Partners es www.molecularpartners.com
¿En qué sector industrial opera Molecular Partners?
Molecular Partners opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
HSDTHelius Medical Technologies Inc
US$ 1.365
(97.25%)
2.23M
VMARVision Marine Technologies Inc
US$ 2.39
(70.71%)
1.4M
SGBXSafe and Green Holdings Corporation
US$ 0.6938
(28.48%)
208.67k
ERNAEterna Therapeutics Inc
US$ 0.5622
(22.75%)
564.94k
ALLKAllakos Inc
US$ 1.07
(21.37%)
29
CRKNCrown Electrokinetics Corporation
US$ 0.0614
(-30.70%)
276.85k
SYRESpyre Therapeutics Inc
US$ 15.11
(-27.36%)
1
RIMEAlgorhythm Holdings Inc
US$ 0.061
(-21.99%)
415.94k
MTRXMatrix Service Co
US$ 10.51
(-18.59%)
1
BLFYBlue Foundry Bancorp
US$ 7.59
(-17.41%)
2
HSDTHelius Medical Technologies Inc
US$ 1.365
(97.25%)
2.23M
VMARVision Marine Technologies Inc
US$ 2.39
(70.71%)
1.4M
RGTIRigetti Computing Inc
US$ 9.60
(7.26%)
1.31M
SHViShares Short Treasury Bond ETF
US$ 110.27
(0.01%)
1.07M
LAESSEALSQ Corporation
US$ 4.00
(9.29%)
781.21k

MOLN Discussion

Ver más
Monksdream Monksdream 3 semanas hace
MOLN, under $6


👍️0
OncoJock OncoJock 2 meses hace
Spoke with a research scientist today at the Memorial Sloan-Kettering Cancer Center who told me about MPO712, a radioDARPin targeted against DLL3-, which is a promising therapeutic target in a wide variety of aggressive tumors, including small cell lung cancer and the neuroendocrine form of prostate cancer. This scientist told me that there are now at least 20 drugs in development targeting DLL3, including bispecific antibodies, tri specific antibodies, radioligands, and antibody-drug conjugates. Apparently DARPins are an entirely new class of drugs, being pioneered by Molecular Partners. These drugs are characterized by structural simplicity and low molecular weight, in contrast to antibody-based drugs which are large, heavy macromolecules.

A little research on the Molecular Partners website confirmed what the scientist told me, including that MPO712 is being prepared for entry into clinical trials in 2025. MOLN will also present posters about 2 other drugs next month at the annual meeting of the American Society of Hematology (ASH), one about MPO533 in acute myeloid leukemia, the other MPO621 an anti-CD47 agent designed as a conditioning agent for patients undergoing stem cell transplant.

-- OJ
👍️0
Monksdream Monksdream 3 meses hace
MOLN under $6
👍️0
Awl416 Awl416 6 meses hace
Don’t blink
👍️0
Monksdream Monksdream 6 meses hace
MOLN
👍️0
Awl416 Awl416 7 meses hace
Whoops
👍️0
TimeFades TimeFades 7 meses hace
Short
👍️0
Man6677 Man6677 3 años hace
MOLN $$$$

https://stockcharts.com/h-sc/ui?s=MOLN


https://finance.yahoo.com/news/molecular-partners-finalizes-license-agreement-060000110.html

GLTA !
👍️0
crudeoil24 crudeoil24 3 años hace
Molecular Partners shares are trading higher after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
👍️0
crudeoil24 crudeoil24 3 años hace
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
👍️0

Su Consulta Reciente

NASDAQ
MOLN
Molecular Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados